Actively Recruiting
Pilot Trial of Transcutaneous Auricular Vagus Nerve Stimulation Device for Treating Moderate to Severe Rosacea
Led by Brigham and Women's Hospital · Updated on 2026-08-14
10
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of transcutaneous auricular vagus nerve stimulation taVNS in people with rosacea who experience moderate to severe flushing or redness. This pilot study aims to assess how this device-based treatment might influence rosacea symptoms and quality of life over a short period. Participants will undergo a single 4-week treatment period where they use the taVNS device. After completing this active intervention, they will be monitored for an additional 4 weeks without treatment to observe the lasting effects. The study focuses on changes in skin redness, quality of life, flushing severity, and mental health measures during and after the treatment. During the 8-week participation, individuals will be regularly assessed with clinical evaluations, questionnaires about their skin condition and mental health, and quality of life surveys. The primary outcomes include changes in clinician-assessed erythema and dermatology quality of life at week 4. Secondary outcomes track these measures plus flushing severity and anxiety and depression scores through week 8. The study is sponsored by Brigham and Womens Hospital.
CONDITIONS
Brief Title
Transcutaneous Auricular Vagus Nerve Stimulation Treatment for Rosacea
Research Team
L
Liset Chacin
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here